Regeneron Pharmaceuticals, Inc. (United States)

Regeneron Pharmaceuticals is a leading biotechnology company developing transformative medicines for serious diseases. Based in Tarrytown, New York, key products include Eylea (aflibercept) for retinal diseases, Dupixent (dupilumab) for atopic dermatitis, asthma, and other inflammatory conditions, Libtayo (cemiplimab) for cancers, and REGEN-COV for COVID-19. Regeneron’s VelociSuite technology platform accelerates drug discovery and development.